# US 2021/0267910 A1 · Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267910 A1
- Document ID: US20210267910A1
- Status: Published application
- Kind: A1
- Application number: 17/325,088
- Filed: 2021-05-19
- Published: 2021-09-02
- Earliest claimed: 2013-08-21
- Assignees: Concordia University
- Applicants: Concordia University
- Inventors: Abhay Singh Chauhan; Eric Andrew Newenhouse; Armin Henry Gerhardt
- Web page: https://patentgrep.com/patent/US20210267910A1

## CPC

- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, Alzheimer's disease, Parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided. The compositions may be topically applied to skin or mucous membranes.

## Claims

### Claim 1

A composition comprising a dendrimer-resveratrol complex, the composition being essentially free of organic solvent, wherein the dendrimer comprises pyrrolidinone surface groups.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition further comprises water.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the aqueous solubility of the resveratrol associated with the dendrimer is at least 10 times greater than the aqueous solubility of neat resveratrol, as measured at pH 7.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the aqueous solubility of the resveratrol associated with the dendrimer is at least 10 times greater than the aqueous solubility of neat resveratrol, as measured at pH 2.5.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the dendrimer comprises poly(amidoamine) (PAMAM), poly(propyleneimine) (PPI), poly(lysine), poly(glycerol) or a hyperbranched structure; wherein the hyperbranched structure is selected from the group consisting of dendrigrafts, polyesters, polyamides, and polyalcohols.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the dendrimer is a generation 4 PAMAM dendrimer comprising a diaminobutane core.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the composition of claim 1 and one or more pharmaceutically acceptable carriers.

### Claim 8 (depends on 1)

The composition of claim 1, further comprising a retinoid, an antioxidant, or a combination thereof.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the antioxidant is selected from the group consisting of ascorbic acid and salts and esters thereof, epichlorocatechin, curcumin, tocopherol and salts and esters thereof, butylated hydroxyl benzoic acids and salts thereof, butylated hydroxytoluene, butylated hydroxyanisole, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, gallic acids and alkyl esters thereof, uric acid and salts and alkyl esters thereof, sorbic acid and salts thereof, amines, sulfhydryl compounds, sodium metabisulfite, dihydroxy fumaric acid and salts thereof, glutathione, and a combination thereof.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the retinoid is retinol.

### Claim 11

A composition comprising a dendrimer-resveratrol complex and a retinoid, the composition being essentially free of organic solvent.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the composition further comprises water.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the aqueous solubility of the resveratrol associated with the dendrimer is at least 10 times greater than the aqueous solubility of neat resveratrol, as measured at pH 7.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the aqueous solubility of the resveratrol associated with the dendrimer is at least 10 times greater than the aqueous solubility of neat resveratrol, as measured at pH 2.5.

### Claim 15 (depends on 11)

The composition of claim 11, wherein the dendrimer comprises poly(amidoamine) (PAMAM), poly(propyleneimine) (PPI), poly(lysine), poly(glycerol) or a hyperbranched structure; wherein the hyperbranched structure is selected from the group consisting of dendrigrafts, polyesters, polyamides, and polyalcohols.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the dendrimer comprises a generation 4 PAMAM dendrimer comprising a diaminobutane core and surface groups comprising amine surface groups, pyrrolidinone surface groups, or a combination thereof.

### Claim 17 (depends on 11)

The composition of claim 11, wherein the retinoid comprises retinol.

### Claim 18 (depends on 11)

The composition of claim 11, further comprising an antioxidant.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the antioxidant is selected from the group consisting of ascorbic acid and salts and esters thereof, epichlorocatechin, curcumin, tocopherol and salts and esters thereof, butylated hydroxyl benzoic acids and salts thereof, butylated hydroxytoluene, butylated hydroxyanisole, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, gallic acids and alkyl esters thereof, uric acid and salts and alkyl esters thereof, sorbic acid and salts thereof, amines, sulfhydryl compounds, sodium metabisulfite, dihydroxy fumaric acid and salts thereof, glutathione, and a combination thereof.

### Claim 20 (depends on 8)

A pharmaceutical composition comprising a therapeutically effective amount of the composition of claim 8 and one or more pharmaceutically acceptable carriers.

### Claim 21 (depends on 11)

A pharmaceutical composition comprising a therapeutically effective amount of the composition of claim 11 and one or more pharmaceutically acceptable carriers.
